In a meta-analysis of 40 studies, people with the 677 TT genotype had a strikingly similar 16% higher odds of coronary heart disease compared with those with the CC genotype: These results support the hypothesis that impaired folate metabolism, resulting in high homocysteine levels, is causally related to increased risk of CHD
0.1% (placebo) Steady State: Achieved after 4-5 weeks of weekly dosing Safety: Nausea (68% at 4.5 mg), vomiting (32%), generally mild-moderate and transient Discontinuation: 14% discontinued due to GI adverse events Appetite Effects: Significant reductions in Visual Analogue Scale (VAS) hunger scores Publication: Lau DCW, et al
The rationale for combining these peptides extends beyond simple additive effects, as BPC-157's gastric pentadecapeptide sequence activates growth factor pathways and nitric oxide systems while TB-500's thymosin beta-4 derivative promotes actin regulation, cell migration, and blood vessel formation through separate receptor interactions
Repeated freeze-thaw cycles degrade the peptide and should be avoided
But the real question isn't which list any peptide lands on